Denali Therapeutics
CIK 0001714899 · Biotech · Public
Small molecule therapeutics that cross the blood-brain barrier to treat neurodegenerative diseases
denalitherapeutics.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $500M
- 1 Form D · Mar 2024
- 32 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 40
- 14 granted · 26 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20232024
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $499,732,711 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1128 | Moderna | — | $556M |
| 1129 | Mariana Oncology | — | — |
| 1130 | OMVAX, INC. | — | — |
| 1131 | Denali Therapeutics | — | $500M |
| 1132 | MS Biotech Holdings, Inc. | — | $59M |
| 1133 | PROLACTA BIOSCIENCE INC | — | $65M |
| 1134 | CalciMedica Subsidiary, Inc. | — | $67M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Jennifer CookDirector
- Jay FlatleyDirector
- Erik HarrisDirector
- Carole HoExecutive Officer
- Peter KleinDirector
- Steve KrognesDirector
- Vicki SatoDirector
- David SchenkeinDirector
- Alexander SchuthExecutive Officer
- Marc Tessier-LavigneDirector
- Nancy ThornberryDirector
- Ryan WattsDirector · Executive Officer
Patents
- ANTI-HER2 Antibodies And Methods Of Use Thereofgranted
- Affinity-based Methods For Using Transferrin Receptor-binding Proteinsapplication
- Processes And Intermediates For The Preparation Of A Pyrimidine Aminopyrazole Compoundapplication
- Formulations Of Protein Molecules Comprising Iduronate 2-SULFATASEgranted
- Solid Forms Of A Compoundgranted
- Anti-transferrin Receptor Fusion Proteins And Methods Of Use Thereofgranted
- Anti-pilra Antibodies, Uses Thereof, And Related Methods And Reagentsapplication
- ANTI-HER2 Antibodies And Methods Of Use Thereofapplication
- Methods For Treating And Monitoring Progranulin-associated Disordersapplication
- Fusion Proteins Comprising Progranulinapplication
- Compounds, Compositions and Methodsapplication
- Modulators Of Eukaryotic Initiation Factor 2B, Compositions And Methodsapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.